Skip to content
Review Open access

Sacubitril/valsartan and prevention of chemotherapy-induced cardiac dysfunction: meta-analysis of randomized trials

Oct 2026 · European Heart Journal · 0 citations

Abstract

Chemotherapy-related cardiac dysfunction (CTRCD) is a major limitation of cardiotoxic cancer therapies. Although global longitudinal strain (GLS) allows early detection of myocardial injury, preventive strategies remain scarce. Angiotensin receptor–neprilysin inhibitors (ARNIs) may offer cardioprotection, but current evidence is limited. To evaluate the efficacy of sacubitril/valsartan in preventing chemotherapy-related cardiac dysfunction, given the clinical need for early cardioprotection. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating sacubitril/valsartan versus control in patients undergoing chemotherapy. PubMed, Embase, and Cochrane databases were searched. Risk ratios (RRs) and mean differences (MDs) with 95% CIs were computed for binary and continuous outcomes. Four RCTs comprising 412 participants were included; 42.7% received ARNI therapy, with follow-up ranging from 6 to 18 months. Compared with control, ARNI significantly preserved left ventricular systolic function (MD 1.47%, 95% CI 0.59 to 2.34; Figure 1A) and attenuated GLS deterioration (MD -0.93%, 95% CI -1.49 to -0.38; Figure 1B). However, ARNI did not significantly reduce the incidence of CTRCD (RR 0.40, 95% CI 0.08-1.97) or all-cause mortality (RR 0.63, 95% CI 0.08-5.0). ARNI increased the risk of hypotension but had no significant effects on NT-proBNP or dyspnea. ARNI therapy improves GLS and LVEF during chemotherapy but has not yet demonstrated reductions in CTRCD or mortality. Hypotension remains a key safety consideration.Graphical AbstractFigure 1

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.